1Herrmann ML, Schleyerbach R, Kirschbaum BJ. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology, 2000, 47 ( 2 - 3 ): 273 - 289.
2Cherwinski HM, Byars N, Ballaron SJ, et al. Leflunomide interferes with pyrimidine nucleotide biosynthesis. Inflamm Res, 1995,44 (8): 317 - 322.
3Fox RI, Herrmann ML, Frangou CG, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol, 1999, 93 (3) :198 - 208.
4Thanos D, Maniatis T. NF-kappa B: a lesson in family values. Cell, 1995, 80(4) :529 -532.
5Blackwell TS, Christman JW. The role of nuclear factor-kappa B in cy tokine gene regulation. Am J Respir Cell Mol Biol, 1997, 17( 1 ) :3 -9.
7Siemasko K, Chong AS, Jack HM, et al. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug le flunomide leads to a block in IgG1 production. J Immunol, 1998, 160 (4) :1581 - 1588.
9Mirmohammadsadegh A, Homey B, Abts HF, et al. Differential modu lation of pro- and anti-inflammatory cytokine receptors by N - ( 4 - trifluoromethylphenyl) - 2 - cyano - 3 - hydroxy - crotonic acid amide (A77 1726), the physiologically active metabolite of the novel immu nomodulator leflunomide. Biochem Pharmacol, 1998, 55 (9): 1523 -1529.
10Reich K, Hummel KM, Beckmann I, et al. Treatment of severe psoria sis and psoriatic arthritis with leflunomide. Br J Dermatol, 2002,146 (2) :335 -336.
